Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such fields as anti-tumor, anti-infectives,CNS diseases and metabolic diseases as well as autoimmune diseases. As a key national high-tech enterprise and a national technology innovation exemplary enterprise, Hansoh Pharma has long maintained top 100 of global pharmaceutical enterprises and top 3 of China’s Best Industrial Enterprises in Pharmaceutical R&D Pipeline, which was listed in Hong Kong Stock Market in June, 2019.(HK03692)

 

Hansoh Pharma has excellent R&D capabilities and over 20 years of R&D experience. With 1,521 professional researchers, we have created a R&D system that covers the entire process from frontier information collection, compound design and screening, pharmacological and toxicological research to clinical medical research, and established a number of national R&D institutions including National Enterprise Technology Center, Postdoctoral Research Center, and Key National Laboratory.

 

Hansoh Pharma is highly efficient in discovering innovative macromolecule and small-molecule drugs, and its R&D layout covers the fields of mAb, ADC, siRNA, BsAb and fusion protein products. Hansoh Pharma has so far marketed 6 innovative drugs, and has more than 30 innovative drug programs in different clinical stages with over 40 clinical trials in progress, forming a competitive pipeline.

 

Our innovative drugs on the market include: Ameile (aumolertinib mesylate tablets), China's first original third-generation EGFR-TKI innovative drug; XINYUE (inebilizumab injections), the world's only humanized anti-CD19 mAb approved for the treatment of adult patients with AQP4 antibody-positive NMOSD; Hengmu (tenofovir amibufenamide tablets), China's first original oral anti-HBV drug; Hansoh Xinfu (flumatinib mesylate tablets), China's first original second-generation innovative drug for chronic myeloid leukemia; Fulaimei (PEG-loxenatide for injection), China's first original long-acting GLP-1 hypoglycemic drug and the world's first PEGylated long-acting hypoglycemic drug; and Mailingda (morinidazole sodium chloride injection), the world's first innovative nitroimidazole anti-anaerobic drug in 40 years. All above have been included in the National Reimbursement Drug List, and Hansoh Pharma has successfully transformed itself into an innovative biopharma company.

 

Hansoh Pharma has always maintained dynamic consistency with global advanced access levels by continuously designing and building production facilities and production lines in accordance with international advanced standards and using advanced production equipment. Our production quality system has been officially certified by FDA of the United States, EMA of the European Union and PMDA of Japan, and finished preparations and APIs have been approved for marketing in Europe, America, Japan, etc.

 

Looking ahead, Hansoh Pharma will further deepen its innovation-driven strategy, leverage the global innovation ecosystem, explore and develop more innovative drugs to meet global urgent clinical needs, and make unremitting efforts to improve human health and quality of life.